1
|
Li X, Tan Y, Song J, Lu H, Bian Y, Cai W. Combined intravenous and intra-arterial thrombolysis in hyperacute cerebral ischemia without significant corresponding vascular occlusion/stenosis: A Preliminary investigation. Heliyon 2024; 10:e29998. [PMID: 38707359 PMCID: PMC11066378 DOI: 10.1016/j.heliyon.2024.e29998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 04/18/2024] [Accepted: 04/18/2024] [Indexed: 05/07/2024] Open
Abstract
Objective In this study, we assessed the efficacy and safety of various thrombolytic treatment protocols in patients with hyperacute cerebral infarction. Methods Patients diagnosed with acute ischemic stroke within 6 h of symptom onset and with brain computer tomography angiography confirming the absence of major vessel stenosis or occlusion were eligible for this study. The enrolled patients were subsequently randomized into two groups: all the groups received the standard intravenous thrombolysis treatment with rt-PA (0.9 mg/kg), and the experimental group underwent sequential intra-arterial thrombolysis treatment with alteplase (0.3 mg/kg, with a maximum dose of 22 mg), administered directly into the target vessel via a microcatheter. Both groups were closely monitored for changes in their National Institutes of Health Stroke Scale (NIHSS) score, modified Rankin scale score, hemorrhage rate, all-cause mortality rate, and the rate of favorable outcomes at 90 ± 7 days. Results Ninety-four participants were enrolled in this study, with both the control and experimental groups initiating intravenous injection of rt-PA at a median time of 29 min. For the experimental group, the median time for arterial puncture was 123 min. Baseline data for both groups were similar (P > 0.05). Hemorrhagic transformation occurred in 24.47 % (23 patients), with a lower intracranial hemorrhage rate observed in the experimental group compared to the control group (15.2 % vs 33.3 %, P < 0.05). Asymptomatic hemorrhage rates were 8.7 % for the experimental group and 12.5 % for the control group, with no hemorrhage detected in other locations. Post-treatment median NIHSS scores were lower in the experimental group than in the control group (7 vs 9, P < 0.05), but short-term NIHSS scores were similar (P > 0.05). A higher proportion of patients in the experimental group achieved favorable outcomes compared to the control group (87.0 % vs 43.8 %, P < 0.05). Conclusion In patients with acute ischemic stroke with an onset time of ≤6 h and no major intracranial vessel occlusion, combining rt-PA intravenous thrombolysis with intra-arterial thrombolysis via a microcatheter might yield superior functional outcomes.
Collapse
Affiliation(s)
| | | | - Jinzhao Song
- Department of Cerebrovascular Diseases Center, Guigang People's Hospital, Guigang 537100, Guangxi, China
| | - Hongying Lu
- Department of Cerebrovascular Diseases Center, Guigang People's Hospital, Guigang 537100, Guangxi, China
| | - Yuan Bian
- Department of Cerebrovascular Diseases Center, Guigang People's Hospital, Guigang 537100, Guangxi, China
| | - Wenqiang Cai
- Department of Cerebrovascular Diseases Center, Guigang People's Hospital, Guigang 537100, Guangxi, China
| |
Collapse
|
2
|
Duan Q, Lyu J, Cheng K, Wang X, Meng Z, Wu X, Chen W, Wang G, Niu Q, Li X, Bian Y, Han D, Guo W, Yang S, Bian X, Lan Y, Wang L, Zhang T, Duan C, Tian C, Lou X. MRI Assessment of Brain Frailty and Clinical Outcome in Patients With Acute Posterior Perforating Artery Infarction. J Magn Reson Imaging 2024; 59:340-349. [PMID: 37183874 DOI: 10.1002/jmri.28768] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 04/22/2023] [Accepted: 04/24/2023] [Indexed: 05/16/2023] Open
Abstract
BACKGROUND Global brain health has gained increasing attention recently. Imaging markers of brain frailty have been related to functional outcomes in previous studies on anterior circulation; however, little data are available on imaging markers and posterior circulation. PURPOSE To investigate the impact of brain frailty on functional outcomes in patients with acute perforating artery infarction (PAI) of the posterior circulation. STUDY TYPE Prospective. POPULATION One hundred patients (60.78 ± 9.51 years, 72% men) with acute posterior circulation PAI (determined by diffusion-weighted magnetic resonance imaging (MRI)/time-of-flight MR angiography). FIELD STRENGTH/SEQUENCE T1- and T2-weighted fast spin echo, T2-weighted fluid-attenuated inversion recovery, diffusion-weighted echo planar, gradient echo (susceptibility-weight imaging), and 3D time-of-flight MR angiography sequences at 3.0 T. ASSESSMENT Periventricular and deep white matter hyperintensities (WMH), enlarged perivascular spaces (EPVS) in the basal ganglia and centrum semiovale area, lacunes, cerebral microbleeds (CMB), and total brain frailty score by calculating the above imaging characters were rated visually by three radiologists with 9, 10, and 11 years of experience and one neuroradiologist with 12. Infarction volume was assessed using baseline diffusion-weighted imaging (DWI) data obtained within 24 hours of symptom onset. A modified Rankin Scale (mRS) score >1 on day 90 defined an adverse functional outcome. Associations between the imaging markers of brain frailty and functional outcomes were assessed. STATISTICAL TESTS Fisher's exact test, Mann-Whitney U test, and multivariable binary logistic regression. A P value <0.05 was considered statistically significant. RESULTS Adverse prognoses (mRS > 1) were observed in 34 (34%) patients. Infarction volume, periventricular WMH, deep WMH, basal ganglia EPVS, CMB, and the brain frailty score were significantly associated with adverse functional outcomes. An increased brain frailty score was significantly associated with unfavorable mRS score on day 90 (odds ratio 1.773, 95% confidence interval 1.237-2.541). DATA CONCLUSION Advanced MRI imaging markers of brain frailty, individually or combined as a total brain frailty score, were associated with worse functional outcomes after acute posterior circulation PAI. LEVEL OF EVIDENCE 3 TECHNICAL EFFICACY: Stage 3.
Collapse
Affiliation(s)
- Qi Duan
- Department of Radiology, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, China
| | - Jinhao Lyu
- Department of Radiology, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, China
| | - Kun Cheng
- Department of Radiology, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, China
| | - Xueyang Wang
- Department of Radiology, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, China
| | - Zhihua Meng
- Department of Radiology, Yuebei People's Hospital, Shaoguan, China
| | - Xiaoyan Wu
- Department of Radiology, Anshan Changda Hospital, Anshan, China
| | - Wen Chen
- Department of Radiology, Shiyan Taihe Hospital, Shiyan, China
| | - Guohua Wang
- Department of Radiology, Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao, China
| | - Qingliang Niu
- Department of Radiology, WeiFang Traditional Chinese Hospital, Weifang, China
| | - Xin Li
- Department of Radiology, The Second Hospital of Jilin University, Jilin, China
| | - Yitong Bian
- Department of Radiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Dan Han
- Department of Radiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China
| | - Weiting Guo
- Department of Radiology, Shanxi Provincial People's Hospital, Xi'an, China
| | - Shuai Yang
- Department of Radiology, Xiangya Hospital Central South University, Changsha, China
| | - Xiangbing Bian
- Department of Radiology, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, China
| | - Yina Lan
- Department of Radiology, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, China
| | - Liuxian Wang
- Department of Radiology, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, China
| | - Tingyang Zhang
- Department of Radiology, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, China
| | - Caohui Duan
- Department of Radiology, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, China
| | - Chenglin Tian
- Department of Neurology, Chinese PLA General Hospital, Beijing, China
| | - Xin Lou
- Department of Radiology, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, China
| |
Collapse
|
3
|
Saima B, Mikel T, Maria B, Yolanda S, Juan ÁC, Victor VM, Laura P, Montserrat R, Carme GM, Alan M, Joaquín S. Progressive Lacunar Atrokes: A Predictive Score. J Stroke Cerebrovasc Dis 2022; 31:106510. [DOI: 10.1016/j.jstrokecerebrovasdis.2022.106510] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2021] [Revised: 04/01/2022] [Accepted: 04/08/2022] [Indexed: 02/05/2023] Open
|
4
|
Wei H, Wang Y, Zhang Y, Du S, Shen J, Li X, Yan H, Wang N, Zhu J, Wang Y, Cai Z. Outcomes and risk factors of perforating and non-perforating middle cerebral artery infarctions after intravenous thrombolysis. J Thromb Thrombolysis 2022; 53:722-730. [PMID: 35028829 DOI: 10.1007/s11239-021-02620-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 11/29/2021] [Indexed: 11/24/2022]
Abstract
The clinical symptoms of perforating arteries differ, and responses to intravenous thrombolytic therapy are heterogeneous. Here, we investigated the effect of intravenous thrombolytic therapy and the related factors influencing acute perforating and non-perforating middle cerebral artery infarctions. We analyzed 320 patients with acute middle cerebral artery infarction who received alteplase thrombolysis within 4.5 h of onset at two stroke centers from January 2016 to December 2019. Outcome measures included rates of a favorable functional outcome (modified Rankin Scale scores of 0-2), distribution of modified Rankin Scale scores, intracranial hemorrhage, and symptomatic cerebral hemorrhage at 14 days, with comparisons between perforating artery and non-perforating artery cerebral infarction groups. In the perforating vessel disease group, 12 cases (17.4%) of intracranial hemorrhage occurred, with symptomatic cerebral hemorrhage in three cases (4.3%); there were no significant differences between the perforating and non-perforating vessel disease groups (all P > 0.05). In the perforating vessel disease group, the only significant prognostic factor was the National Institutes of Health Stroke Scale score before thrombolysis (Exp(B) = 1.365; 95% confidence interval [CI] 1.124-1.659; P = 0.002), and the only significant risk factor for hemorrhagic transformation was previous perforator disease (Exp(B) = 0.078; P = 0.038). Regardless of whether an acute infarction is perforating or non-perforating, intravenous thrombolytic therapy can yield a favorable outcome. Therefore, intravenous thrombolysis should be actively administered to treat perforating artery infarctions with a high risk of disability.
Collapse
Affiliation(s)
- Hongyu Wei
- Department of Neurology, The Affiliated Suzhou Science & Technology Town Hospital of Nanjing Medical University, Suzhou, China
| | - Yiqing Wang
- Department of Neurology, The Affiliated Suzhou Science & Technology Town Hospital of Nanjing Medical University, Suzhou, China
| | - Yongjin Zhang
- Department of Neurology, Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, China
| | - Shouyun Du
- Department of Neurology, Guanyun People's Hospital, Lianyungang, China
| | - Jiahui Shen
- Department of Neurology, The Affiliated Suzhou Science & Technology Town Hospital of Nanjing Medical University, Suzhou, China
| | - Xiaojing Li
- Department of Neurology, The Affiliated Suzhou Science & Technology Town Hospital of Nanjing Medical University, Suzhou, China
| | - Hongjie Yan
- Department of Neurology, Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, China
| | - Nizhuan Wang
- Artificial Intelligence & Neuro-Informatics Engineering (ARINE) Laboratory, School of Computer Engineering, Jiangsu Ocean University, Lianyungang, 222023, China
| | - Jianbing Zhu
- Department of Radiology, The Affiliated Suzhou Science & Technology Town Hospital of Nanjing Medical University, Suzhou, China
| | - Yi Wang
- Department of Radiology, The Affiliated Suzhou Science & Technology Town Hospital of Nanjing Medical University, Suzhou, China
| | - Zenglin Cai
- Department of Neurology, The Affiliated Suzhou Science & Technology Town Hospital of Nanjing Medical University, Suzhou, China.
| |
Collapse
|
5
|
Hong L, Ling Y, Su Y, Yang L, Lin L, Parsons M, Cheng X, Dong Q. Hemispheric cerebral blood flow predicts outcome in acute small subcortical infarcts. J Cereb Blood Flow Metab 2021; 41:2534-2545. [PMID: 34435912 PMCID: PMC8504947 DOI: 10.1177/0271678x211029884] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The association between baseline perfusion measures and clinical outcomes in patients with acute small subcortical infarcts (SSIs) has not been studied in detail. Post-processed acute perfusion CT and follow-up diffusion-weighted imaging of 71 patients with SSIs were accurately co-registered. Relative perfusion values were calculated from the perfusion values of the infarct lesion divided by those of the mirrored contralateral area. The association between perfusion measures with clinical outcomes and the interaction with intravenous thrombolysis were studied. Additionally, the perfusion measures for patients having perfusion CT before and after thrombolysis were compared. Higher contralateral hemispheric cerebral blood flow (CBF) was the only independent predictor of an excellent clinical outcome (modified Rankin Scale of 0-1) at 3 months (OR = 1.3, 95% CI 1.1-1.4, P = 0.001) amongst all the perfusion parameters, and had a significant interaction with thrombolysis (P = 0.04). Patients who had perfusion CT after thrombolysis demonstrated a better perfusion profile (relative CBF ≥1) than those who had perfusion CT before thrombolysis (After:45.5%, Before:21.1%, P = 0.03). This study implies that for patients with SSIs, hemispheric CBF is a predictor of clinical outcome and has an influence on the effect of intravenous thrombolysis.
Collapse
Affiliation(s)
- Lan Hong
- Department of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China
| | - Yifeng Ling
- Department of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China
| | - Ya Su
- Department of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China
| | - Lumeng Yang
- Department of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China
| | - Longting Lin
- Department of Neurology, Liverpool Hospital, University of New South Wales South Western Sydney Clinical School, The Ingham Institute for Applied Medical Research, Liverpool, Australia
| | - Mark Parsons
- Department of Neurology, Liverpool Hospital, University of New South Wales South Western Sydney Clinical School, The Ingham Institute for Applied Medical Research, Liverpool, Australia
| | - Xin Cheng
- Department of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China
| | - Qiang Dong
- Department of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China
| |
Collapse
|
6
|
Karaszewski B, Wyszomirski A, Jabłoński B, Werring DJ, Tomaka D. Efficacy and Safety of Intravenous rtPA in Ischemic Strokes Due to Small-Vessel Occlusion: Systematic Review and Meta-Analysis. Transl Stroke Res 2021; 12:406-415. [PMID: 33641037 PMCID: PMC8055574 DOI: 10.1007/s12975-021-00890-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Revised: 12/14/2020] [Accepted: 01/11/2021] [Indexed: 12/26/2022]
Abstract
Intravenous recombinant tissue plasminogen activator (iv-rtPA) has been routinely used to treat ischemic stroke for 25 years, following large clinical trials. However, there are few prospective studies on the efficacy and safety of this therapy in strokes attributed to cerebral small vessel disease (SVD). We evaluated functional outcome (modified Rankin scale, mRS) and symptomatic intracerebral hemorrhage (sICH) using all available data on the effects of iv-rtPA in SVD-related ischemic stroke (defined either using neuroimaging, clinical features, or both). Using fixed-effect and random-effects models, we calculated the pooled effect estimates with regard to excellent and favorable outcomes (mRS=0-1 and 0-2 respectively, at 3 months), and the rate of sICH. Twenty-three studies fulfilled the eligibility criteria, 11 of which were comparative, and there were only 3 randomized clinical trials. In adjusted analyses, there was an increased odds of excellent outcome (adjusted OR=1.53, 95% CI: 1.29-1.82, I2: 0%) or favorable outcome (adjusted OR=1.68, 95% CI: 1.31-2.15,I2: 0%) in patients who received iv-rtPA compared with placebo. Across the six studies which reported it, the incidence of sICH was higher in the treatment group (M-H RR = 8.83, 95% CI: 2.76-28.27). The pooled rate of sICH in patients with SVD administered iv-rtPA was only 0.72% (95% CI: 0.12%-1.64%). We conclude that when ischemic stroke attributed to SVD is considered separately, available data on the effects of iv-rtPA therapy are insufficient for the highest level of recommendation, but it seems to be safe. Although further therapeutic trials in SVD-related ischemic stroke appear to be justified, our findings should not prevent its continued use for this group of patients in clinical practice.
Collapse
Affiliation(s)
- Bartosz Karaszewski
- Department of Adult Neurology, Division of Neurology, Faculty of Medicine, Medical University of Gdansk, Poland, Gdansk, Poland.
- Department of Adult Neurology, University Clinical Center in Gdansk, Poland, Debinki 7, 80-211, Gdansk, Poland.
- Main Expert in Stroke Medicine for the Polish Ministry of Health, Warsaw, Poland.
| | - Adam Wyszomirski
- Department of Adult Neurology, Division of Neurology, Faculty of Medicine, Medical University of Gdansk, Poland, Gdansk, Poland
| | - Bartosz Jabłoński
- Department of Adult Neurology, Division of Neurology, Faculty of Medicine, Medical University of Gdansk, Poland, Gdansk, Poland
- Department of Adult Neurology, University Clinical Center in Gdansk, Poland, Debinki 7, 80-211, Gdansk, Poland
| | - David J Werring
- Stroke Research Centre, University College London, Queen Square Institute of Neurology, London, UK
| | - Dominika Tomaka
- Department of Adult Neurology, University Clinical Center in Gdansk, Poland, Debinki 7, 80-211, Gdansk, Poland
| |
Collapse
|
7
|
Barow E, Boutitie F, Cheng B, Cho TH, Ebinger M, Endres M, Fiebach JB, Fiehler J, Ford I, Galinovic I, Nickel A, Puig J, Roy P, Wouters A, Magnus T, Thijs V, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Simonsen CZ, Gerloff C, Thomalla G. Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial. JAMA Neurol 2020; 76:641-649. [PMID: 30907934 DOI: 10.1001/jamaneurol.2019.0351] [Citation(s) in RCA: 44] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Importance The rationale for intravenous thrombolysis in patients with lacunar infarcts is debated, since it is hypothesized that the microvascular occlusion underlying lacunar infarcts might not be susceptible to pharmacological reperfusion treatment. Objective To study the efficacy and safety of intravenous thrombolysis among patients with lacunar infarcts. Design, Setting, and Participants This exploratory secondary post hoc analysis of the WAKE-UP trial included patients who were screened and enrolled between September 2012 and June 2017 (with final follow-up in September 2017). The WAKE-UP trial was a multicenter, double-blind, placebo-controlled randomized clinical trial to study the efficacy and safety of intravenous thrombolysis with alteplase in patients with an acute stroke of unknown onset time, guided by magnetic resonance imaging. All 503 patients randomized in the WAKE-UP trial were reviewed for lacunar infarcts. Diagnosis of lacunar infarcts was based on magnetic resonance imaging and made by consensus of 2 independent investigators blinded to clinical information. Main Outcomes and Measures The primary efficacy variable was favorable outcome defined by a score of 0 to 1 on the modified Rankin Scale at 90 days after stroke, adjusted for age and severity of symptoms. Results Of the 503 patients randomized in the WAKE-UP trial, 108 patients (including 74 men [68.5%]) had imaging-defined lacunar infarcts, whereas 395 patients (including 251 men [63.5%]) had nonlacunar infarcts. Patients with lacunar infarcts were younger than patients with nonlacunar infarcts (mean age [SD], 63 [12] years vs 66 [12] years; P = .003). Of patients with lacunar infarcts, 55 (50.9%) were assigned to treatment with alteplase and 53 (49.1%) to receive placebo. Treatment with alteplase was associated with higher odds of favorable outcome, with no heterogeneity of treatment outcome between lacunar and nonlacunar stroke subtypes. In patients with lacunar strokes, a favorable outcome was observed in 31 of 53 patients (59%) in the alteplase group compared with 24 of 52 patients (46%) in the placebo group (adjusted odds ratio [aOR], 1.67 [95% CI, 0.77-3.64]). There was 1 death and 1 symptomatic intracranial hemorrhage according to Safe Implementation of Thrombolysis in Stroke-Monitoring Study criteria in the alteplase group, while no death and no symptomatic intracranial hemorrhage occurred in the placebo group. The distribution of the modified Rankin Scale scores 90 days after stroke also showed a nonsignificant shift toward better outcomes in patients with lacunar infarcts treated with alteplase, with an adjusted common odds ratio of 1.94 (95% CI, 0.95-3.93). Conclusions and Relevance While the WAKE-UP trial was not powered to demonstrate the efficacy of treatment in subgroups of patients, the results indicate that the association of intravenous alteplase with functional outcome does not differ in patients with imaging-defined lacunar infarcts compared with those experiencing other stroke subtypes.
Collapse
Affiliation(s)
- Ewgenia Barow
- Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Florent Boutitie
- Hospices Civils de Lyon, Service de Biostatistique, Lyon, France.,Université Lyon 1, Villeurbanne, France.,Centre National de la Recherche Scientifique, Unité de Mixte de Recherche 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbanne, France
| | - Bastian Cheng
- Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Tae-Hee Cho
- Department of Stroke Medicine, Université Claude Bernard Lyon 1, CREATIS Centre National de la Recherche Scientifique Unité de Mixte de Recherche 5220, Institut National de la Santé et de la Recherche Médicale U1206, Institut National des Sciences Appliquées-Lyon, Lyon, France.,Hospices Civils de Lyon, Lyon, France
| | - Martin Ebinger
- Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.,Neurologie der Rehaklinik Medical Park Humboldtmühle, Berlin, Germany
| | - Matthias Endres
- Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.,Klinik und Hochschulambulanz für Neurologie, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Jochen B Fiebach
- Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Jens Fiehler
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Ian Ford
- Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom
| | - Ivana Galinovic
- Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Alina Nickel
- Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Josep Puig
- Department of Radiology, Institut de Diagnostic per la Image, Hospital Dr Josep Trueta, Institut d'Investigació Biomèdica de Girona, Salt, Girona, Spain
| | - Pascal Roy
- Hospices Civils de Lyon, Service de Biostatistique, Lyon, France
| | - Anke Wouters
- Department of Neurology, University Hospitals Leuven, Leuven, Belgium.,Department of Neurosciences, Experimental Neurology, Katholieke Universiteit Leuven, Leuven, Belgium.,Vlaams Instituut voor Biotechnologie, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium
| | - Tim Magnus
- Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Vincent Thijs
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.,Department of Neurology, Austin Health, Heidelberg, Victoria, Australia
| | - Robin Lemmens
- Department of Neurology, University Hospitals Leuven, Leuven, Belgium.,Department of Neurosciences, Experimental Neurology, Katholieke Universiteit Leuven, Leuven, Belgium.,Vlaams Instituut voor Biotechnologie, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium
| | - Keith W Muir
- Institute of Neuroscience & Psychology, University of Glasgow, Glasgow, United Kingdom
| | - Norbert Nighoghossian
- Department of Stroke Medicine, Université Claude Bernard Lyon 1, CREATIS Centre National de la Recherche Scientifique Unité de Mixte de Recherche 5220, Institut National de la Santé et de la Recherche Médicale U1206, Institut National des Sciences Appliquées-Lyon, Lyon, France.,Hospices Civils de Lyon, Lyon, France
| | - Salvador Pedraza
- Department of Radiology, Institut de Diagnostic per la Image, Hospital Dr Josep Trueta, Institut d'Investigació Biomèdica de Girona, Salt, Girona, Spain
| | - Claus Z Simonsen
- Department of Neurology, Aarhus University Hospital, Aarhus, Denmark
| | - Christian Gerloff
- Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Götz Thomalla
- Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | | |
Collapse
|
8
|
Das AS, Regenhardt RW, Feske SK, Gurol ME. Treatment Approaches to Lacunar Stroke. J Stroke Cerebrovasc Dis 2019; 28:2055-2078. [PMID: 31151838 PMCID: PMC7456600 DOI: 10.1016/j.jstrokecerebrovasdis.2019.05.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 04/15/2019] [Accepted: 05/02/2019] [Indexed: 12/12/2022] Open
Abstract
Lacunar strokes are appropriately named for their ability to cavitate and form ponds or "little lakes" (Latin: lacune -ae meaning pond or pit is a diminutive form of lacus meaning lake). They account for a substantial proportion of both symptomatic and asymptomatic ischemic strokes. In recent years, there have been several advances in the management of large vessel occlusions. New therapies such as non-vitamin K antagonist oral anticoagulants and left atrial appendage closure have recently been developed to improve stroke prevention in atrial fibrillation; however, the treatment of small vessel disease-related strokes lags frustratingly behind. Since Fisher characterized the lacunar syndromes and associated infarcts in the late 1960s, there have been no therapies specifically targeting lacunar stroke. Unfortunately, many therapeutic agents used for the treatment of ischemic stroke in general offer only a modest benefit in reducing recurrent stroke while adding to the risk of intracerebral hemorrhage and systemic bleeding. Escalation of antithrombotic treatments beyond standard single antiplatelet agents has not been effective in long-term lacunar stroke prevention efforts, unequivocally increasing intracerebral hemorrhage risk without providing a significant benefit. In this review, we critically review the available treatments for lacunar stroke based on evidence from clinical trials. For several of the major drugs, we summarize the adverse effects in the context of this unique patient population. We also discuss the role of neuroprotective therapies and neural repair strategies as they may relate to recovery from lacunar stroke.
Collapse
Affiliation(s)
- Alvin S Das
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Robert W Regenhardt
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Steven K Feske
- Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Mahmut Edip Gurol
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
| |
Collapse
|
9
|
|
10
|
Lu Y, Yu J, Hu J, Tan Y, Wu J, Zhao Y, Liu X. Predictive Value of A2HD Scoring for Transient Symptoms Associated with Infarction. Med Sci Monit 2019; 25:52-60. [PMID: 30601800 PMCID: PMC6327777 DOI: 10.12659/msm.911941] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Background Effective early management of cerebral infarction patients with transient ischemic attack (TIA) is undermined by an inability to predict who is at highest risk of stroke. Material/Methods A total of 577 TIA patients with symptoms lasting no more than 1 hour were prospectively investigated and divided into a TIA group and a transient symptoms associated with infarction (TSI) group based on diffusion-weighted magnetic resonance imaging findings after hospital admission. The baseline characteristics, symptoms of TIA, features of disease onset, and findings from clinical examinations were compared between the 2 groups. Factors related to TSI were further analyzed. Results Of 577 TIA patients, 127 patients were in the TSI group and 450 were in the TIA group. Anterior circulation events, hemiplegia, aphasia, multiple seizures, maximal duration, atrial fibrillation, and hypointense plaques were included as risk factors for stroke in a model of multivariate analysis, and results showed that hemiplegia, aphasia, multiple seizures, and atrial fibrillation were independent risk factors for TSI. In the final mode, the area under the curve (AUC) was 0.766 (95% confidence interval: 0.729–0.800). According to the A2HD score and odds ratio, hemiplegia (score 2), aphasia (score 2), multiple seizures (score 2), and atrial fibrillation (score 1) were scored, and any increment in the score increased the risk for cerebral infarction by 1.893-fold (95% confidence interval: 1.643–2.181). Conclusions Risk of TSI seems to be highly predictable. The A2HD score can be used in clinical practice to identify high-risk cerebral infarction patients with TIA who need emergency diagnosis and treatment.
Collapse
Affiliation(s)
- You Lu
- Department of Neurology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (mainland)
| | - Jia Yu
- Department of Neurology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (mainland)
| | - Jian Hu
- Department of Radiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (mainland)
| | - Yan Tan
- Department of Neurology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (mainland)
| | - Jiayan Wu
- Department of Neurology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (mainland)
| | - Yanxin Zhao
- Department of Neurology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (mainland)
| | - Xueyuan Liu
- Department of Neurology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (mainland)
| |
Collapse
|
11
|
Zivanovic Z, Gubi M, Vlahovic D, Milicevic M, Jovicevic M, Lucic A, Ruzicka-Kaloci S, Radovanovic B, Zikic TR, Zarkov M, Popovic N, Slankamenac P. Patients with Acute Lacunar Infarction Have Benefit from Intravenous Thrombolysis. J Stroke Cerebrovasc Dis 2018; 28:435-440. [PMID: 30409747 DOI: 10.1016/j.jstrokecerebrovasdis.2018.10.020] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Revised: 09/21/2018] [Accepted: 10/13/2018] [Indexed: 11/16/2022] Open
Abstract
INTRODUCTION Usefulness of intravenous thrombolysis in patients with acute lacunar cerebral infarction is questionable. The aim of this study was to evaluate the efficacy and safety of intravenous thrombolysis in patients with lacunar infarction in comparison with patients with nonlacunar infarction as well as with patients with lacunar infarction who were not treated with intravenous thrombolysis. MATERIALS AND METHODS In the first part of the study, among patients with acute ischemic stroke treated with intravenous thrombolysis, characteristics and outcomes of 46 patients with lacunar and 221 patients with nonlacunar infarction were compared. In the second part, 46 patients with lacunar infarction treated with intravenous thrombolysis were compared with 45 lacunar infarction patients who were not treated with intravenous thrombolysis. RESULTS Patients with lacunar infarction had a lower National Institutes of Health Stroke Scale score (9.2 versus 13.9, P < .001), a greater Alberta Stroke Program Early computed tomography (CT) score (9.7 versus 9.2, P = .002), a lower prevalence of atrial fibrillation (6.5% versus 41.2%, P < .001), and significantly more frequently an excellent outcome after 3 months (76.1% versus 36.2%, P < .001) compared with patients with nonlacunar infarction. Among patients with lacunar infarction, an excellent outcome at discharge was significantly more frequent in the intravenous thrombolysis group (41.3% versus 15.6%, P = .01), and the length of hospitalization was significantly shorter (9.5 days versus 14.3 days, P = .002). There was no hemorrhagic transformation among patients with lacunar infarction treated with intravenous thrombolysis. CONCLUSION Intravenous thrombolysis has proven to be effective and safe in patients with lacunar infarction and should always be applied if there are no absolute contraindications.
Collapse
Affiliation(s)
- Zeljko Zivanovic
- University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; Clinic of Neurology, Clinical Centre of Vojvodina, Novi Sad, Serbia.
| | - Marina Gubi
- University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia.
| | - Dmitar Vlahovic
- Clinic of Neurology, Clinical Centre of Vojvodina, Novi Sad, Serbia.
| | - Marija Milicevic
- Clinic of Neurology, Clinical Centre of Vojvodina, Novi Sad, Serbia.
| | - Mirjana Jovicevic
- University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; Clinic of Neurology, Clinical Centre of Vojvodina, Novi Sad, Serbia.
| | - Aleksandra Lucic
- University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; Clinic of Neurology, Clinical Centre of Vojvodina, Novi Sad, Serbia.
| | - Svetlana Ruzicka-Kaloci
- University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; Clinic of Neurology, Clinical Centre of Vojvodina, Novi Sad, Serbia.
| | | | - Tamara Rabi Zikic
- University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; Clinic of Neurology, Clinical Centre of Vojvodina, Novi Sad, Serbia.
| | - Marija Zarkov
- University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; Clinic of Neurology, Clinical Centre of Vojvodina, Novi Sad, Serbia.
| | - Nemanja Popovic
- University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; Clinic of Neurology, Clinical Centre of Vojvodina, Novi Sad, Serbia.
| | - Petar Slankamenac
- University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; Clinic of Neurology, Clinical Centre of Vojvodina, Novi Sad, Serbia.
| |
Collapse
|
12
|
Naqvi I, Simpkins AN, Cullison K, Elliott E, Reyes D, Leigh R, Lynch JK. Recurrent thrombolysis of a stuttering lacunar infarction captured on serial MRIs. eNeurologicalSci 2018; 13:14-17. [PMID: 30450428 PMCID: PMC6224319 DOI: 10.1016/j.ensci.2018.10.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2018] [Accepted: 10/28/2018] [Indexed: 01/08/2023] Open
Abstract
Lacunar strokes account for about a fourth of all ischemic strokes. Pontine infarcts often present with stuttering symptoms, referred to as pontine warning syndrome (PWS). Patients presenting with fluctuating symptoms can appear to have rapidly improving symptoms and thus often go untreated despite the risk of recurrent deficits. MRI carries a higher sensitivity in detecting posterior circulation strokes compared to computed topagraphy, but does not always indicate irreversible injury. Here we present the first description of a stuttering lacune, captured radiographically on serial magnetic resonance imaging (MRI), that was initially averted with the administration of intravenous (IV) tissue plasminogen activator (tPA), only to return a month later and progress on imaging despite re-administration of tPA. During the first admission, our patient had spontaneous resolution of symptoms with complete reversal on restricted diffusion soon after IV tPA administration. On the second admission, the stuttering symptoms returned as did the same pontine lesion. Although his stuttering lesions lasted for several days, and the pontine lesion did ultimately progress to partial infarction on MRI, he was discharged home without neurologic deficits. Our case suggests that tPA may be of benefit in patients with lacunar pontine strokes even if symptoms rapidly improve or resolve.
Collapse
Affiliation(s)
- Imama Naqvi
- Section on Stroke Diagnostics and Therapeutics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United States
| | - Alexis N Simpkins
- Section on Stroke Diagnostics and Therapeutics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United States
| | - Kaylie Cullison
- Section on Stroke Diagnostics and Therapeutics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United States
| | - Emily Elliott
- Walter Reed National Military Medical Center, Bethesda, MD, United States
| | - Dennys Reyes
- Section on Stroke Diagnostics and Therapeutics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United States
| | - Richard Leigh
- Section on Stroke Diagnostics and Therapeutics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United States
| | - John K Lynch
- Section on Stroke Diagnostics and Therapeutics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United States
| |
Collapse
|
13
|
Gauberti M, Potzeha F, Vivien D, Martinez de Lizarrondo S. Impact of Bradykinin Generation During Thrombolysis in Ischemic Stroke. Front Med (Lausanne) 2018; 5:195. [PMID: 30018956 PMCID: PMC6037726 DOI: 10.3389/fmed.2018.00195] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Accepted: 06/14/2018] [Indexed: 12/22/2022] Open
Abstract
Ischemic stroke is one of the leading causes of death and disability worldwide. Current medical management in the acute phase is based on the activation of the fibrinolytic cascade by intravenous injection of a plasminogen activator (such as tissue-type plasminogen activator, tPA) that promotes restauration of the cerebral blood flow and improves stroke outcome. Unfortunately, the use of tPA is associated with deleterious effects such as hemorrhagic transformation, symptomatic brain edema, and angioedema, which limit the efficacy of this therapeutic strategy. Preclinical and clinical evidence suggests that intravenous thrombolysis generates large amounts of bradykinin, a peptide with potent pro-inflammatory, and pro-edematous effects. This tPA-triggered generation of bradykinin could participate in the deleterious effects of thrombolysis and is a potential target to improve neurological outcome in tPA-treated patients. The present review aims at summarizing current evidence linking thrombolysis, bradykinin generation, and neurovascular damage.
Collapse
Affiliation(s)
- Maxime Gauberti
- Normandie Univ, UNICAEN, Institut National de la Santé et de la Recherche Médicale UMR-S U1237, "Physiopathology and Imaging of Neurological Disorders" PhIND, Caen, France.,Department of Diagnostic Imaging and Interventional Radiology, Centre Hospitalier Universitaire Caen Côte de Nacre, Caen, France
| | - Fanny Potzeha
- Normandie Univ, UNICAEN, Institut National de la Santé et de la Recherche Médicale UMR-S U1237, "Physiopathology and Imaging of Neurological Disorders" PhIND, Caen, France
| | - Denis Vivien
- Normandie Univ, UNICAEN, Institut National de la Santé et de la Recherche Médicale UMR-S U1237, "Physiopathology and Imaging of Neurological Disorders" PhIND, Caen, France.,Department of Clinical Research, Centre Hospitalier Universitaire Caen, Caen, France
| | - Sara Martinez de Lizarrondo
- Normandie Univ, UNICAEN, Institut National de la Santé et de la Recherche Médicale UMR-S U1237, "Physiopathology and Imaging of Neurological Disorders" PhIND, Caen, France
| |
Collapse
|
14
|
Tian H, Parsons MW, Levi CR, Cheng X, Aviv RI, Spratt NJ, Kleinig TJ, O'Brien B, Butcher KS, Lin L, Zhang J, Dong Q, Chen C, Bivard A. Intravenous Thrombolysis May Not Improve Clinical Outcome of Acute Ischemic Stroke Patients Without a Baseline Vessel Occlusion. Front Neurol 2018; 9:405. [PMID: 29928251 PMCID: PMC5997810 DOI: 10.3389/fneur.2018.00405] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Accepted: 05/17/2018] [Indexed: 11/13/2022] Open
Abstract
Background and Purpose: The benefit of thrombolysis in ischemic stroke patients without a visible vessel occlusion still requires investigation. This study tested the hypothesis that non-lacunar stroke patients with no visible vessel occlusion on baseline imaging would have a favorable outcome regardless of treatment with alteplase. Methods: We utilized a prospectively collected registry of ischemic stroke patients [the International Stroke Perfusion Imaging Registry (INSPIRE)] who had baseline computed tomographic perfusion and computed tomographic angiography. The rates of patients achieving modified Rankin Scale (mRS) 0-1 were compared between alteplase treated and untreated patients using logistic regression to generate odds ratios. Results: Of 1569 patients in the INSPIRE registry, 1,277 were eligible for inclusion. Of these, 306 (24%) had no identifiable occlusion and were eligible for alteplase, with 141 (46%) of these patients receiving thrombolysis. The treated and untreated groups had significantly different median baseline National Institutes of Health Stroke Scale (NIHSS) [alteplase 8, interquartile range (IQR) 5-10, untreated 6, IQR 4-8, P < 0.001] and median volume of baseline perfusion lesion [alteplase 5.6 mL, IQR 1.3-17.7 mL, untreated 2.6 mL, IQR 0-6.7 mL, P < 0.001]. After propensity analysis, alteplase treated patients without a vessel occlusion were less likely to have an excellent outcome (mRS 0-1; 56%) than untreated (78.8%, OR, 0.42, 95% confidence interval, 0.24-0.75, P = 0.003). Conclusions: In this non-randomized comparison, alteplase treatment in patients without an identifiable vessel occlusion did not result in higher rates of favorable outcome compared to untreated. However, treated patients displayed less favorable baseline prognostic factors than the untreated group. Further studies may be required to confirm this data.
Collapse
Affiliation(s)
- Huiqiao Tian
- Department of Neurology, John Hunter Hospital, University of Newcastle, Newcastle, NSW, Australia
| | - Mark W Parsons
- Department of Neurology, John Hunter Hospital, University of Newcastle, Newcastle, NSW, Australia
| | - Christopher R Levi
- Department of Neurology, John Hunter Hospital, University of Newcastle, Newcastle, NSW, Australia
| | - Xin Cheng
- Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
| | - Richard I Aviv
- Division of Neuroradiology, Department of Medical Imaging, University of Toronto and Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Neil J Spratt
- Department of Neurology, John Hunter Hospital, University of Newcastle, Newcastle, NSW, Australia
| | - Timothy J Kleinig
- Department of Neurology, Royal Adelaide Hospital, Adelaide, SA, Australia
| | - Billy O'Brien
- Department of Neurology, Gosford Hospital, Gosford, NSW, Australia
| | - Kenneth S Butcher
- Division of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
| | - Longting Lin
- Department of Neurology, John Hunter Hospital, University of Newcastle, Newcastle, NSW, Australia
| | - Jingfen Zhang
- Department of Neurology, Baotou Central Hospital, Baotou, China
| | - Qiang Dong
- Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
| | - Chushuang Chen
- Department of Neurology, John Hunter Hospital, University of Newcastle, Newcastle, NSW, Australia
| | - Andrew Bivard
- Department of Neurology, John Hunter Hospital, University of Newcastle, Newcastle, NSW, Australia
| |
Collapse
|
15
|
Kunz WG, Fabritius MP, Sommer WH, Höhne C, Scheffler P, Rotkopf LT, Fendler WP, Sabel BO, Meinel FG, Dorn F, Ertl-Wagner B, Reiser MF, Thierfelder KM. Effect of stroke thrombolysis predicted by distal vessel occlusion detection. Neurology 2018; 90:e1742-e1750. [PMID: 29678936 DOI: 10.1212/wnl.0000000000005519] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Accepted: 02/26/2018] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE Among ischemic stroke patients with negative CT angiography (CTA), we aimed to determine the predictive value of enhanced distal vessel occlusion detection using CT perfusion postprocessing (waveletCTA) for the treatment effect of IV thrombolysis (IVT). METHODS Patients were selected from 1,851 consecutive patients who had undergone CT perfusion. Inclusion criteria were (1) significant cerebral blood flow (CBF) deficit, (2) no occlusion on CTA, and (3) infarction confirmed on follow-up. Favorable morphologic response was defined as smaller values of final infarction volume divided by initial CBF deficit volume (FIV/CBF). Favorable functional outcome was defined as modified Rankin Scale score of ≤2 after 90 days and decrease in NIH Stroke Scale score of ≥3 from admission to 24 hours (∆NIHSS). RESULTS Among patients with negative CTA (n = 107), 58 (54%) showed a distal occlusion on waveletCTA. There was no difference between patients receiving IVT (n = 57) vs supportive care (n = 50) regarding symptom onset, early ischemic changes, perfusion mismatch, or admission NIHSS score (all p > 0.05). In IVT-treated patients, the presence of an occlusion was an independent predictor of a favorable morphologic response (FIV/CBF: β -1.43; 95% confidence interval [CI] -1.96, -0.83; p = 0.001) and functional outcome (90-day modified Rankin Scale: odds ratio 7.68; 95% CI 4.33-11.51; p = 0.039; ∆NIHSS: odds ratio 5.76; 95% CI 3.98-8.27; p = 0.013), while it did not predict outcome in patients receiving supportive care (all p > 0.05). CONCLUSION In stroke patients with negative CTA, distal vessel occlusions as detected by waveletCTA are an independent predictor of a favorable response to IVT.
Collapse
Affiliation(s)
- Wolfgang G Kunz
- From the Departments of Radiology (W.G.K., M.P.F., W.H.S., L.T.R., B.O.S., F.G.M., B.E.-W., M.F.R., K.M.T.), Neurology (C.H., P.S.), Nuclear Medicine (W.P.F.), and Neuroradiology (F.D.), University Hospital, LMU Munich; and the Institute of Diagnostic and Interventional Radiology (F.G.M., K.M.T.), University Medical Center Rostock, Germany.
| | - Matthias P Fabritius
- From the Departments of Radiology (W.G.K., M.P.F., W.H.S., L.T.R., B.O.S., F.G.M., B.E.-W., M.F.R., K.M.T.), Neurology (C.H., P.S.), Nuclear Medicine (W.P.F.), and Neuroradiology (F.D.), University Hospital, LMU Munich; and the Institute of Diagnostic and Interventional Radiology (F.G.M., K.M.T.), University Medical Center Rostock, Germany
| | - Wieland H Sommer
- From the Departments of Radiology (W.G.K., M.P.F., W.H.S., L.T.R., B.O.S., F.G.M., B.E.-W., M.F.R., K.M.T.), Neurology (C.H., P.S.), Nuclear Medicine (W.P.F.), and Neuroradiology (F.D.), University Hospital, LMU Munich; and the Institute of Diagnostic and Interventional Radiology (F.G.M., K.M.T.), University Medical Center Rostock, Germany
| | - Christopher Höhne
- From the Departments of Radiology (W.G.K., M.P.F., W.H.S., L.T.R., B.O.S., F.G.M., B.E.-W., M.F.R., K.M.T.), Neurology (C.H., P.S.), Nuclear Medicine (W.P.F.), and Neuroradiology (F.D.), University Hospital, LMU Munich; and the Institute of Diagnostic and Interventional Radiology (F.G.M., K.M.T.), University Medical Center Rostock, Germany
| | - Pierre Scheffler
- From the Departments of Radiology (W.G.K., M.P.F., W.H.S., L.T.R., B.O.S., F.G.M., B.E.-W., M.F.R., K.M.T.), Neurology (C.H., P.S.), Nuclear Medicine (W.P.F.), and Neuroradiology (F.D.), University Hospital, LMU Munich; and the Institute of Diagnostic and Interventional Radiology (F.G.M., K.M.T.), University Medical Center Rostock, Germany
| | - Lukas T Rotkopf
- From the Departments of Radiology (W.G.K., M.P.F., W.H.S., L.T.R., B.O.S., F.G.M., B.E.-W., M.F.R., K.M.T.), Neurology (C.H., P.S.), Nuclear Medicine (W.P.F.), and Neuroradiology (F.D.), University Hospital, LMU Munich; and the Institute of Diagnostic and Interventional Radiology (F.G.M., K.M.T.), University Medical Center Rostock, Germany
| | - Wolfgang P Fendler
- From the Departments of Radiology (W.G.K., M.P.F., W.H.S., L.T.R., B.O.S., F.G.M., B.E.-W., M.F.R., K.M.T.), Neurology (C.H., P.S.), Nuclear Medicine (W.P.F.), and Neuroradiology (F.D.), University Hospital, LMU Munich; and the Institute of Diagnostic and Interventional Radiology (F.G.M., K.M.T.), University Medical Center Rostock, Germany
| | - Bastian O Sabel
- From the Departments of Radiology (W.G.K., M.P.F., W.H.S., L.T.R., B.O.S., F.G.M., B.E.-W., M.F.R., K.M.T.), Neurology (C.H., P.S.), Nuclear Medicine (W.P.F.), and Neuroradiology (F.D.), University Hospital, LMU Munich; and the Institute of Diagnostic and Interventional Radiology (F.G.M., K.M.T.), University Medical Center Rostock, Germany
| | - Felix G Meinel
- From the Departments of Radiology (W.G.K., M.P.F., W.H.S., L.T.R., B.O.S., F.G.M., B.E.-W., M.F.R., K.M.T.), Neurology (C.H., P.S.), Nuclear Medicine (W.P.F.), and Neuroradiology (F.D.), University Hospital, LMU Munich; and the Institute of Diagnostic and Interventional Radiology (F.G.M., K.M.T.), University Medical Center Rostock, Germany
| | - Franziska Dorn
- From the Departments of Radiology (W.G.K., M.P.F., W.H.S., L.T.R., B.O.S., F.G.M., B.E.-W., M.F.R., K.M.T.), Neurology (C.H., P.S.), Nuclear Medicine (W.P.F.), and Neuroradiology (F.D.), University Hospital, LMU Munich; and the Institute of Diagnostic and Interventional Radiology (F.G.M., K.M.T.), University Medical Center Rostock, Germany
| | - Birgit Ertl-Wagner
- From the Departments of Radiology (W.G.K., M.P.F., W.H.S., L.T.R., B.O.S., F.G.M., B.E.-W., M.F.R., K.M.T.), Neurology (C.H., P.S.), Nuclear Medicine (W.P.F.), and Neuroradiology (F.D.), University Hospital, LMU Munich; and the Institute of Diagnostic and Interventional Radiology (F.G.M., K.M.T.), University Medical Center Rostock, Germany
| | - Maximilian F Reiser
- From the Departments of Radiology (W.G.K., M.P.F., W.H.S., L.T.R., B.O.S., F.G.M., B.E.-W., M.F.R., K.M.T.), Neurology (C.H., P.S.), Nuclear Medicine (W.P.F.), and Neuroradiology (F.D.), University Hospital, LMU Munich; and the Institute of Diagnostic and Interventional Radiology (F.G.M., K.M.T.), University Medical Center Rostock, Germany
| | - Kolja M Thierfelder
- From the Departments of Radiology (W.G.K., M.P.F., W.H.S., L.T.R., B.O.S., F.G.M., B.E.-W., M.F.R., K.M.T.), Neurology (C.H., P.S.), Nuclear Medicine (W.P.F.), and Neuroradiology (F.D.), University Hospital, LMU Munich; and the Institute of Diagnostic and Interventional Radiology (F.G.M., K.M.T.), University Medical Center Rostock, Germany
| |
Collapse
|
16
|
Dargazanli C, Arquizan C, Gory B, Consoli A, Labreuche J, Redjem H, Eker O, Decroix JP, Corlobé A, Mourand I, Gaillard N, Ayrignac X, Charif M, Duhamel A, Labeyrie PE, Riquelme C, Ciccio G, Smajda S, Desilles JP, Gascou G, Lefèvre PH, Mantilla-García D, Cagnazzo F, Coskun O, Mazighi M, Riva R, Bourdain F, Labauge P, Rodesch G, Obadia M, Bonafé A, Turjman F, Costalat V, Piotin M, Blanc R, Lapergue B, Wang A, Evrard S, Tchikviladzé M, Gonzalez-Valcarcel J, Di Maria F, Pico F, Rakotoharinandrasana H, Tassan P, Poll R, Corabianu O, de Broucker T, Smadja D, Alamowitch S, Ille O, Manchon E, Garcia PY. Mechanical Thrombectomy for Minor and Mild Stroke Patients Harboring Large Vessel Occlusion in the Anterior Circulation. Stroke 2017; 48:3274-3281. [DOI: 10.1161/strokeaha.117.018113] [Citation(s) in RCA: 66] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2017] [Revised: 08/16/2017] [Accepted: 09/18/2017] [Indexed: 11/16/2022]
Affiliation(s)
- Cyril Dargazanli
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Caroline Arquizan
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Benjamin Gory
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Arturo Consoli
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Julien Labreuche
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Hocine Redjem
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Omer Eker
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Jean-Pierre Decroix
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Astrid Corlobé
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Isabelle Mourand
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Nicolas Gaillard
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Xavier Ayrignac
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Mahmoud Charif
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Alain Duhamel
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Paul-Emile Labeyrie
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Carlos Riquelme
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Gabriele Ciccio
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Stanislas Smajda
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Jean-Philippe Desilles
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Grégory Gascou
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Pierre-Henri Lefèvre
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Daniel Mantilla-García
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Federico Cagnazzo
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Oguzhan Coskun
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Mikael Mazighi
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Roberto Riva
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Frédéric Bourdain
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Pierre Labauge
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Georges Rodesch
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Michael Obadia
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Alain Bonafé
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Francis Turjman
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Vincent Costalat
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Michel Piotin
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Raphaël Blanc
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | - Bertrand Lapergue
- From the Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France (C.D., O.E., C.R., G.G., P.-H.L., D.M.-G., F.C., A.B., V.C.); Department of Neurology, Gui de Chauliac Hospital, Montpellier, France (C.A., A.C., I.M., N.G., X.A., M.C., P.L.); Department of Interventional Neuroradiology, Pierre Wertheimer Hospital, Lyon-Bron, France (B.G., P.-E.L., R.R., F.T.); Department of Interventional Neuroradiology (A.C., O.C., G.R.) and Department of Neurology (J.-P.D., F.B., B.L.), Foch
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Majhadi L, Calvet D, Rosso C, Bartolucci P. Thrombolytic therapy for the treatment of acute ischaemic stroke in adults with homozygous sickle cell disease. BMJ Case Rep 2017; 2017:bcr-2017-220011. [PMID: 28756377 DOI: 10.1136/bcr-2017-220011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Stroke is a significant cause of morbidity and mortality in patients with homozygous sickle cell disease (SCD). A specific large-vessel vasculopathy is often responsible for both haemorrhagic and ischaemic strokes in patients with SCD. Although intravenous thrombolysis has been considered as a therapeutic option for acute ischaemic strokes in SCD, its use remains debated because of an increased risk of spontaneous intracranial haemorrhage reported in this disease. This risk of haemorrhage is mainly supported by the presence of a Moyamoya syndrome often associated with the specific vasculopathy in patients with homozygous SCD. We report two cases of patients with homozygous SCD treated with intravenous thrombolysis for an acute ischaemic stroke without haemorrhagic transformation. Our cases suggest that reperfusion strategy in acute ischaemic stroke in patients with homozygous SCD can be considered once associated Moyamoya syndrome has been ruled out. An international registry would be of interest as these situations are rare.
Collapse
Affiliation(s)
- Loubna Majhadi
- APHP (Assistance publique - Hopitaux de Paris), Servicede Neurologie, Groupe hospitalier Henri-Mondor Albert Chenevier, Créteil, France, Creteil, France
| | - David Calvet
- Department of Neurology, Univ Paris 05, Paris, France
| | - Charlotte Rosso
- Assistance Publique - Hopitaux de Paris, Paris, ÃŽle-de-France, France
| | - Pablo Bartolucci
- Assistance Publique - Hopitaux de Paris, Creteil, ÃŽle-de-France, France
| |
Collapse
|
18
|
Detection of single-phase CTA occult vessel occlusions in acute ischemic stroke using CT perfusion-based wavelet-transformed angiography. Eur Radiol 2017; 27:2657-2664. [DOI: 10.1007/s00330-016-4613-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2016] [Revised: 08/21/2016] [Accepted: 09/15/2016] [Indexed: 10/20/2022]
|
19
|
Mair G, von Kummer R, Adami A, White PM, Adams ME, Yan B, Demchuk AM, Farrall AJ, Sellar RJ, Sakka E, Palmer J, Perry D, Lindley RI, Sandercock PAG, Wardlaw JM. Arterial Obstruction on Computed Tomographic or Magnetic Resonance Angiography and Response to Intravenous Thrombolytics in Ischemic Stroke. Stroke 2016; 48:353-360. [PMID: 28008093 PMCID: PMC5266422 DOI: 10.1161/strokeaha.116.015164] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Revised: 11/01/2016] [Accepted: 11/11/2016] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE Computed tomographic angiography and magnetic resonance angiography are used increasingly to assess arterial patency in patients with ischemic stroke. We determined which baseline angiography features predict response to intravenous thrombolytics in ischemic stroke using randomized controlled trial data. METHODS We analyzed angiograms from the IST-3 (Third International Stroke Trial), an international, multicenter, prospective, randomized controlled trial of intravenous alteplase. Readers, masked to clinical, treatment, and outcome data, assessed prerandomization computed tomographic angiography and magnetic resonance angiography for presence, extent, location, and completeness of obstruction and collaterals. We compared angiography findings to 6-month functional outcome (Oxford Handicap Scale) and tested for interactions with alteplase, using ordinal regression in adjusted analyses. We also meta-analyzed all available angiography data from other randomized controlled trials of intravenous thrombolytics. RESULTS In IST-3, 300 patients had prerandomization angiography (computed tomographic angiography=271 and magnetic resonance angiography=29). On multivariable analysis, more extensive angiographic obstruction and poor collaterals independently predicted poor outcome (P<0.01). We identified no significant interaction between angiography findings and alteplase effect on Oxford Handicap Scale (P≥0.075) in IST-3. In meta-analysis (5 trials of alteplase or desmoteplase, including IST-3, n=591), there was a significantly increased benefit of thrombolytics on outcome (odds ratio>1 indicates benefit) in patients with (odds ratio, 2.07; 95% confidence interval, 1.18-3.64; P=0.011) versus without (odds ratio, 0.88; 95% confidence interval, 0.58-1.35; P=0.566) arterial obstruction (P for interaction 0.017). CONCLUSIONS Intravenous thrombolytics provide benefit to stroke patients with computed tomographic angiography or magnetic resonance angiography evidence of arterial obstruction, but the sample was underpowered to demonstrate significant treatment benefit or harm among patients with apparently patent arteries. CLINICAL TRIAL REGISTRATION URL: http://www.isrctn.com. Unique identifier: ISRCTN25765518.
Collapse
Affiliation(s)
- Grant Mair
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.)
| | - Rüdiger von Kummer
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.)
| | - Alessandro Adami
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.)
| | - Philip M White
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.)
| | - Matthew E Adams
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.)
| | - Bernard Yan
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.)
| | - Andrew M Demchuk
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.)
| | - Andrew J Farrall
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.)
| | - Robin J Sellar
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.)
| | - Eleni Sakka
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.)
| | - Jeb Palmer
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.)
| | - David Perry
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.)
| | - Richard I Lindley
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.)
| | - Peter A G Sandercock
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.)
| | - Joanna M Wardlaw
- From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.).
| | | |
Collapse
|
20
|
Giralt-Steinhauer E, Ois A, Abilleira S, Urra X, Cardona-Portela P, Gomis M, Castellanos M, Molina C, Martí-Fàbregas J, Pellisé A, Cànovas D, Gómez-Choco M, Kuprinski J, Cocho D, Roquer J. Frequency and outcome of total anterior circulation strokes without intracranial large-vessel occlusion. Eur J Neurol 2016; 24:11-17. [DOI: 10.1111/ene.13187] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Accepted: 09/16/2016] [Indexed: 11/30/2022]
Affiliation(s)
- E. Giralt-Steinhauer
- Neurovascular Research Group; Neurology Department; Hospital del Mar; Barcelona Spain
| | - A. Ois
- Neurovascular Research Group; Neurology Department; Hospital del Mar; Barcelona Spain
| | - S. Abilleira
- Stroke Programme; Catalan Agency for Health Information, Assessment and Quality (CAHIAQ); Barcelona Spain
| | - X. Urra
- Hospital Clínic; Barcelona Spain
| | | | - M. Gomis
- Hospital GermansTrias i Pujol de Badalona; Badalona Spain
| | - M. Castellanos
- Hospital Universitari JosepTrueta de Girona; Girona Spain
| | - C. Molina
- Hospital Universitari de la Valld'Hebron; Barcelona Spain
| | | | - A. Pellisé
- Hospital Universitari Joan XXIII de Tarragona; Tarragona Spain
| | - D. Cànovas
- Hospital Parc Taulí de Sabadell; Barcelona Spain
| | | | - J. Kuprinski
- Hospital Universitari Mútua Terrassa; Barcelona Spain
- Healthcare Sciences; MMU; Manchester UK
| | - D. Cocho
- Hospital de Granollers; Granollers Spain
| | - J. Roquer
- Neurovascular Research Group; Neurology Department; Hospital del Mar; Barcelona Spain
| | | |
Collapse
|
21
|
Guillon B, Bourcier R, Toulgoat F, de Gaalon S, Gaultier-Lintia A, Sévin M. Gestione dell’infarto cerebrale acuto. Neurologia 2016. [DOI: 10.1016/s1634-7072(16)80382-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
22
|
Ajili N, Decroix JP, Preda C, Labreuche J, Lopez D, Bejot Y, Michel P, Sévin-Allouet M, Sibon I, Vergnet S, Wang A, Sanda N, Mazighi M, Bourdain F, Lapergue B. Impact of thrombolysis in acute ischaemic stroke without occlusion: an observational comparative study. Eur J Neurol 2016; 23:1380-6. [PMID: 27222165 DOI: 10.1111/ene.13042] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2015] [Accepted: 04/04/2016] [Indexed: 11/28/2022]
Abstract
BACKGROUND AND PURPOSE The impact of intravenous recombinant tissue plasminogen activator (IV-rtPA) in patients with acute ischaemic stroke (AIS) but no arterial occlusion is currently a matter of debate. This study aimed to assess functional outcome of such patients with respect to IV-rtPA use. METHODS A retrospective case-control analysis was performed comparing the outcome of AIS patients without arterial occlusion with or without IV-rtPA use. Patients were selected from prospective consecutive observational registries of five European university hospitals. The primary study outcome was excellent outcome at 3 months after stroke, as defined by a modified Rankin Scale (mRS) 0-1. RESULTS A total of 488 patients without arterial occlusion documented by angiography were included in the present study; 300 received IV-rtPA and 188 did not. No between-group difference was found for excellent outcome before and after adjustment for baseline characteristics (adjusted odds ratio for no IV-rtPA use 0.79, 95% confidence interval 0.51-1.24, P = 0.31). Similar results were found for favourable outcome (defined as a 90-day mRS of 0-2) whereas a higher rate of early neurological improvement was found in IV-rtPA-treated patients (adjusted odds ratio 1.99; 95% confidence interval 1.29-3.07, P = 0.002). Sensitivity analyses yielded similar results. CONCLUSIONS Our study suggests that AIS patients without visible arterial occlusion treated with IV-rtPA may have no better outcome at 3 months than those untreated. However, only a randomized controlled trial would provide a definitive answer about the impact of rtPA in acute stroke patients without occlusion. Until then, these patients should be treated by rtPA as recommended.
Collapse
Affiliation(s)
- N Ajili
- Division of Neurology, Stroke Centre, Foch Hospital, University Versailles Saint-Quentin en Yvelines, Suresnes, France
| | - J P Decroix
- Division of Neurology, Stroke Centre, Foch Hospital, University Versailles Saint-Quentin en Yvelines, Suresnes, France
| | - C Preda
- Laboratoire de Mathématiques Paul Painlevé, UMR CNRS 8524, Lille, France
| | - J Labreuche
- Department of Biostatistics, Lille University Medical Centre, Lille, France
| | - D Lopez
- Division of Neurology, Stroke Centre, Foch Hospital, University Versailles Saint-Quentin en Yvelines, Suresnes, France
| | - Y Bejot
- Department of Neurology, University Hospital and Medical School of Dijon, Dijon, France
| | - P Michel
- Neurology Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| | - M Sévin-Allouet
- Department of Neurology, Nantes University Hospital, Nantes, France
| | - I Sibon
- Université Bordeaux 2, CHU Bordeaux, Pole de Neurosciences Cliniques, Unité neuro-vasculaire, Bordeaux, France
| | - S Vergnet
- Université Bordeaux 2, CHU Bordeaux, Pole de Neurosciences Cliniques, Unité neuro-vasculaire, Bordeaux, France
| | - A Wang
- Division of Neurology, Stroke Centre, Foch Hospital, University Versailles Saint-Quentin en Yvelines, Suresnes, France
| | - N Sanda
- Division of Neurology, Stroke Centre, Foch Hospital, University Versailles Saint-Quentin en Yvelines, Suresnes, France
| | - M Mazighi
- Department of Neurology and Stroke Centre, Lariboisière Hospital, Paris, France
| | - F Bourdain
- Division of Neurology, Stroke Centre, Foch Hospital, University Versailles Saint-Quentin en Yvelines, Suresnes, France
| | - B Lapergue
- Division of Neurology, Stroke Centre, Foch Hospital, University Versailles Saint-Quentin en Yvelines, Suresnes, France
| |
Collapse
|
23
|
Brown MD, Burton JH, Nazarian DJ, Promes SB. Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department. Ann Emerg Med 2016; 66:322-333.e31. [PMID: 26304253 DOI: 10.1016/j.annemergmed.2015.06.031] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
24
|
Yang L, Cao W, Wu F, Ling Y, Cheng X, Dong Q. Predictors of clinical outcome in patients with acute perforating artery infarction. J Neurol Sci 2016; 365:108-13. [PMID: 27206885 DOI: 10.1016/j.jns.2016.03.048] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Revised: 03/29/2016] [Accepted: 03/30/2016] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE We aimed to determine the predictive factors for super-acute perforating artery infarctions (PAI) involving lenticulostriate arteries infarctions (LSAI), anterior pontine arteries infarctions (APAI) and thalamic arteries infarctions (TAI). Whether intravenous thrombolysis (iv-tPA) therapy would influence the clinical outcome was also studied. METHODS We analyzed 84 consecutive patients within 12h of stroke symptom onset from January 2008 to June 2015. All patients had an imaging-proven acute infarction in the perforating territory of LSA (n=53), TA (n=21) and APA (n=10). Favorable clinical outcome was defined as modified Rankin Scale ≤1 at 90days. Patients were divided into groups according to clinical outcome, lesion location and thrombolysis therapy. Baseline demographic data, past medical history, National Institutes of Health Stroke Scale (NIHSS) score and infarction volume were compared between groups. RESULTS Eighty-four patients were recruited (median age: 61y; 67.9% male). All patients with TAI (n=21), 34/53 (64.2%) patients with LSAI and 4/10 (40%) patients with APAI achieved favorable clinical outcome (mRS≤1). Ninety-day clinical outcome was associated with age, previous stroke, baseline NIHSS, infarct location, infarct volume. Intravenous thrombolysis improved 24h NIHSS, but was not significantly associated with favorable outcome at 90days. In multivariate analysis, only previous stroke/TIA (OR 0.09, 95%CI 0.01-0.68, p=0.020) and infarct volume (OR 0.64, 95%CI 0.43-0.96, p=0.032) were independently associated with the outcome of acute PAI at 90days. CONCLUSIONS Previous stroke/TIA, infarct location and infarct volume were independently associated with the short-term clinical outcome of acute PAI.
Collapse
Affiliation(s)
- Lumeng Yang
- Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
| | - Wenjie Cao
- Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
| | - Fei Wu
- Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
| | - Yifeng Ling
- Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
| | - Xin Cheng
- Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
| | - Qiang Dong
- Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China; State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China.
| |
Collapse
|
25
|
Pan YT, Lee JD, Lin YH, Huang YC, Weng HH, Lee M, Wu CY, Hsu HL, Yang HT, Hsu CY, Lee TH, Liu SJ, Peng TY, Liou CW, Chang KC, Huang YC. Comparisons of outcomes in stroke subtypes after intravenous thrombolysis. SPRINGERPLUS 2016; 5:47. [PMID: 26835227 PMCID: PMC4718911 DOI: 10.1186/s40064-016-1666-y] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Accepted: 01/04/2016] [Indexed: 11/12/2022]
Abstract
The purpose of this study was to analyze the outcomes and complications between stroke subtypes after intravenous thrombolysis. A total of 471 patients with acute ischemic stroke after intravenous thrombolysis from January 2007 to April 2014 were enrolled and classified according to the Trial of Org 10172 in Acute Stroke Treatment. A multivariate logistic regression model was used to evaluate the outcomes and complications among stroke subtypes after adjusting for baseline variables. Of the 471 patients, 117 (25.1 %) had large-artery atherosclerosis (LAA), 148 (31.8 %) had cardioembolism (CE), 82 (17.6 %) had small vessel disease (SVD), 119 (25.5 %) had undetermined etiology, and 5 (1.1 %) had other determined etiology. The patients with SVD had the mildest initial stroke severity and highest ratio of good and favorable outcomes, whereas those with CE had a higher rate of symptomatic intracranial hemorrhage (sICH) than those with SVD. After adjusting for confounding factors, the ratio of favorable outcome in the patients with SVD stroke was higher than in those with LAA. SVD was associated with a significantly lower rate of any hemorrhage compared to other stroke subtypes, whereas there were no differences in sICH or mortality between stroke subtypes. A lower initial National Institutes of Health Stroke Scale score was associated with good and favorable outcomes, and lower rates of sICH and mortality. The patients with SVD after intravenous thrombolysis had better outcomes and a lower rate of hemorrhage even after adjusting for confounding factors. Stroke severity was an independent factor associated with better functional outcomes, sICH and mortality.
Collapse
Affiliation(s)
- Yi-Ting Pan
- Department of Neurology, Chang Gung Memorial Hospital, Chang-Gung University College of Medicine, 6 West Chia-Pu Road, Putz City, Chiayi County Taiwan
| | - Jiann-Der Lee
- Department of Neurology, Chang Gung Memorial Hospital, Chang-Gung University College of Medicine, 6 West Chia-Pu Road, Putz City, Chiayi County Taiwan
| | - Ya-Hui Lin
- Department of Neurology, Chang Gung Memorial Hospital, Chang-Gung University College of Medicine, 6 West Chia-Pu Road, Putz City, Chiayi County Taiwan
| | - Ying-Chih Huang
- Department of Neurology, Chang Gung Memorial Hospital, Chang-Gung University College of Medicine, 6 West Chia-Pu Road, Putz City, Chiayi County Taiwan
| | - Hsu-Huei Weng
- Department of Diagnostic Radiology, Chang Gung Memorial Hospital, Chang-Gung University College of Medicine, Putz City, Chiayi County Taiwan
| | - Meng Lee
- Department of Neurology, Chang Gung Memorial Hospital, Chang-Gung University College of Medicine, 6 West Chia-Pu Road, Putz City, Chiayi County Taiwan
| | - Chih-Ying Wu
- Department of Neurology, Chang Gung Memorial Hospital, Chang-Gung University College of Medicine, 6 West Chia-Pu Road, Putz City, Chiayi County Taiwan
| | - Huan-Lin Hsu
- Department of Neurology, Chang Gung Memorial Hospital, Chang-Gung University College of Medicine, 6 West Chia-Pu Road, Putz City, Chiayi County Taiwan
| | - Hsin-Ta Yang
- Department of Neurology, Chang Gung Memorial Hospital, Chang-Gung University College of Medicine, 6 West Chia-Pu Road, Putz City, Chiayi County Taiwan
| | - Chia-Yu Hsu
- Department of Neurology, Chang Gung Memorial Hospital, Chang-Gung University College of Medicine, 6 West Chia-Pu Road, Putz City, Chiayi County Taiwan
| | - Tsong-Hai Lee
- Department of Neurology, Stroke Center, Chang Gung Memorial Hospital Linkou Medical Center, Chang Gung University College of Medicine, Taoyuan County, Taiwan
| | - Shan-Jin Liu
- Department of Neurology, Stroke Center, Chang Gung Memorial Hospital Linkou Medical Center, Chang Gung University College of Medicine, Taoyuan County, Taiwan
| | - Tsung-Yi Peng
- Department of Neurology, Stroke Center, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Keelung City, Taiwan
| | - Chia-Wei Liou
- Department of Neurology, Stroke Center, Chang Gung Memorial Hospital Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung City, Taiwan
| | - Ku-Chou Chang
- Department of Neurology, Stroke Center, Chang Gung Memorial Hospital Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung City, Taiwan
| | - Yen-Chu Huang
- Department of Neurology, Chang Gung Memorial Hospital, Chang-Gung University College of Medicine, 6 West Chia-Pu Road, Putz City, Chiayi County Taiwan
| |
Collapse
|
26
|
Mair G, von Kummer R, Morris Z, von Heijne A, Bradey N, Cala L, Peeters A, Farrall AJ, Adami A, Potter G, Cohen G, Sandercock PAG, Lindley RI, Wardlaw JM. Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke. Neurology 2015; 86:118-25. [PMID: 26658907 PMCID: PMC4731690 DOI: 10.1212/wnl.0000000000002236] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Accepted: 09/01/2015] [Indexed: 11/30/2022] Open
Abstract
Objective: To investigate whether the location and extent of the CT hyperdense artery sign (HAS) at presentation affects response to IV alteplase in the randomized controlled Third International Stroke Trial (IST-3). Methods: All prerandomization and follow-up (24–48 hours) CT brain scans in IST-3 were assessed for HAS presence, location, and extent by masked raters. We assessed whether HAS grew, persisted, shrank, or disappeared at follow-up, the association with 6-month functional outcome, and effect of alteplase. IST-3 is registered (ISRCTN25765518). Results: HAS presence (vs absence) independently predicted poor 6-month outcome (increased Oxford Handicap Scale [OHS]) on adjusted ordinal regression analysis (odds ratio [OR] 0.66, p < 0.001). Outcome was worse in patients with more (vs less) extensive HAS (OR 0.61, p = 0.027) but not in proximal (vs distal) HAS (p = 0.420). Increasing age was associated with more HAS growth at follow-up (OR 1.01, p = 0.013). Treatment with alteplase increased HAS shrinkage/disappearance at follow-up (OR 0.77, p = 0.006). There was no significant difference in HAS shrinkage with alteplase in proximal (vs distal) or more (vs less) extensive HAS (p = 0.516 and p = 0.580, respectively). There was no interaction between presence vs absence of HAS and benefit of alteplase on 6-month OHS (p = 0.167). Conclusions: IV alteplase promotes measurable reduction in HAS regardless of HAS location or extent. Alteplase increased independence at 6 months in patients with and without HAS. Classification of evidence: This study provides Class I evidence that for patients within 6 hours of ischemic stroke with a CT hyperdense artery sign, IV alteplase reduced intra-arterial hyperdense thrombus.
Collapse
Affiliation(s)
- Grant Mair
- From the Division of Neuroimaging Sciences (G.M., Z.M., A.J.F., G.C., J.M.W.) and the Division of Clinical Neurosciences (P.A.G.S.), University of Edinburgh, UK; the Department of Neuroradiology (R.v.K.), Dresden University Stroke Centre, Germany; Danderyd Hospital (A.v.H.), Stockholm, Sweden; Neuroradiology (N.B.), James Cook University Hospital, Middlesborough, UK; School of Pathology and Laboratory Medicine (L.C.), University of Western Australia, Perth; Cliniques Universitaires St Luc (A.P.), Neurologie, Belgium; Stroke Center (A.A.), Sacro Cuore-Don Calabria Hospital, Negrar, Italy; the Department of Neuroradiology (G.P.), Salford Royal NHS Foundation Trust, Manchester, UK; and the Westmead Hospital Clinical School and The George Institute for Global Health (R.I.L.), University of Sydney, Australia
| | - Rüdiger von Kummer
- From the Division of Neuroimaging Sciences (G.M., Z.M., A.J.F., G.C., J.M.W.) and the Division of Clinical Neurosciences (P.A.G.S.), University of Edinburgh, UK; the Department of Neuroradiology (R.v.K.), Dresden University Stroke Centre, Germany; Danderyd Hospital (A.v.H.), Stockholm, Sweden; Neuroradiology (N.B.), James Cook University Hospital, Middlesborough, UK; School of Pathology and Laboratory Medicine (L.C.), University of Western Australia, Perth; Cliniques Universitaires St Luc (A.P.), Neurologie, Belgium; Stroke Center (A.A.), Sacro Cuore-Don Calabria Hospital, Negrar, Italy; the Department of Neuroradiology (G.P.), Salford Royal NHS Foundation Trust, Manchester, UK; and the Westmead Hospital Clinical School and The George Institute for Global Health (R.I.L.), University of Sydney, Australia
| | - Zoe Morris
- From the Division of Neuroimaging Sciences (G.M., Z.M., A.J.F., G.C., J.M.W.) and the Division of Clinical Neurosciences (P.A.G.S.), University of Edinburgh, UK; the Department of Neuroradiology (R.v.K.), Dresden University Stroke Centre, Germany; Danderyd Hospital (A.v.H.), Stockholm, Sweden; Neuroradiology (N.B.), James Cook University Hospital, Middlesborough, UK; School of Pathology and Laboratory Medicine (L.C.), University of Western Australia, Perth; Cliniques Universitaires St Luc (A.P.), Neurologie, Belgium; Stroke Center (A.A.), Sacro Cuore-Don Calabria Hospital, Negrar, Italy; the Department of Neuroradiology (G.P.), Salford Royal NHS Foundation Trust, Manchester, UK; and the Westmead Hospital Clinical School and The George Institute for Global Health (R.I.L.), University of Sydney, Australia
| | - Anders von Heijne
- From the Division of Neuroimaging Sciences (G.M., Z.M., A.J.F., G.C., J.M.W.) and the Division of Clinical Neurosciences (P.A.G.S.), University of Edinburgh, UK; the Department of Neuroradiology (R.v.K.), Dresden University Stroke Centre, Germany; Danderyd Hospital (A.v.H.), Stockholm, Sweden; Neuroradiology (N.B.), James Cook University Hospital, Middlesborough, UK; School of Pathology and Laboratory Medicine (L.C.), University of Western Australia, Perth; Cliniques Universitaires St Luc (A.P.), Neurologie, Belgium; Stroke Center (A.A.), Sacro Cuore-Don Calabria Hospital, Negrar, Italy; the Department of Neuroradiology (G.P.), Salford Royal NHS Foundation Trust, Manchester, UK; and the Westmead Hospital Clinical School and The George Institute for Global Health (R.I.L.), University of Sydney, Australia
| | - Nick Bradey
- From the Division of Neuroimaging Sciences (G.M., Z.M., A.J.F., G.C., J.M.W.) and the Division of Clinical Neurosciences (P.A.G.S.), University of Edinburgh, UK; the Department of Neuroradiology (R.v.K.), Dresden University Stroke Centre, Germany; Danderyd Hospital (A.v.H.), Stockholm, Sweden; Neuroradiology (N.B.), James Cook University Hospital, Middlesborough, UK; School of Pathology and Laboratory Medicine (L.C.), University of Western Australia, Perth; Cliniques Universitaires St Luc (A.P.), Neurologie, Belgium; Stroke Center (A.A.), Sacro Cuore-Don Calabria Hospital, Negrar, Italy; the Department of Neuroradiology (G.P.), Salford Royal NHS Foundation Trust, Manchester, UK; and the Westmead Hospital Clinical School and The George Institute for Global Health (R.I.L.), University of Sydney, Australia
| | - Lesley Cala
- From the Division of Neuroimaging Sciences (G.M., Z.M., A.J.F., G.C., J.M.W.) and the Division of Clinical Neurosciences (P.A.G.S.), University of Edinburgh, UK; the Department of Neuroradiology (R.v.K.), Dresden University Stroke Centre, Germany; Danderyd Hospital (A.v.H.), Stockholm, Sweden; Neuroradiology (N.B.), James Cook University Hospital, Middlesborough, UK; School of Pathology and Laboratory Medicine (L.C.), University of Western Australia, Perth; Cliniques Universitaires St Luc (A.P.), Neurologie, Belgium; Stroke Center (A.A.), Sacro Cuore-Don Calabria Hospital, Negrar, Italy; the Department of Neuroradiology (G.P.), Salford Royal NHS Foundation Trust, Manchester, UK; and the Westmead Hospital Clinical School and The George Institute for Global Health (R.I.L.), University of Sydney, Australia
| | - André Peeters
- From the Division of Neuroimaging Sciences (G.M., Z.M., A.J.F., G.C., J.M.W.) and the Division of Clinical Neurosciences (P.A.G.S.), University of Edinburgh, UK; the Department of Neuroradiology (R.v.K.), Dresden University Stroke Centre, Germany; Danderyd Hospital (A.v.H.), Stockholm, Sweden; Neuroradiology (N.B.), James Cook University Hospital, Middlesborough, UK; School of Pathology and Laboratory Medicine (L.C.), University of Western Australia, Perth; Cliniques Universitaires St Luc (A.P.), Neurologie, Belgium; Stroke Center (A.A.), Sacro Cuore-Don Calabria Hospital, Negrar, Italy; the Department of Neuroradiology (G.P.), Salford Royal NHS Foundation Trust, Manchester, UK; and the Westmead Hospital Clinical School and The George Institute for Global Health (R.I.L.), University of Sydney, Australia
| | - Andrew J Farrall
- From the Division of Neuroimaging Sciences (G.M., Z.M., A.J.F., G.C., J.M.W.) and the Division of Clinical Neurosciences (P.A.G.S.), University of Edinburgh, UK; the Department of Neuroradiology (R.v.K.), Dresden University Stroke Centre, Germany; Danderyd Hospital (A.v.H.), Stockholm, Sweden; Neuroradiology (N.B.), James Cook University Hospital, Middlesborough, UK; School of Pathology and Laboratory Medicine (L.C.), University of Western Australia, Perth; Cliniques Universitaires St Luc (A.P.), Neurologie, Belgium; Stroke Center (A.A.), Sacro Cuore-Don Calabria Hospital, Negrar, Italy; the Department of Neuroradiology (G.P.), Salford Royal NHS Foundation Trust, Manchester, UK; and the Westmead Hospital Clinical School and The George Institute for Global Health (R.I.L.), University of Sydney, Australia
| | - Alessandro Adami
- From the Division of Neuroimaging Sciences (G.M., Z.M., A.J.F., G.C., J.M.W.) and the Division of Clinical Neurosciences (P.A.G.S.), University of Edinburgh, UK; the Department of Neuroradiology (R.v.K.), Dresden University Stroke Centre, Germany; Danderyd Hospital (A.v.H.), Stockholm, Sweden; Neuroradiology (N.B.), James Cook University Hospital, Middlesborough, UK; School of Pathology and Laboratory Medicine (L.C.), University of Western Australia, Perth; Cliniques Universitaires St Luc (A.P.), Neurologie, Belgium; Stroke Center (A.A.), Sacro Cuore-Don Calabria Hospital, Negrar, Italy; the Department of Neuroradiology (G.P.), Salford Royal NHS Foundation Trust, Manchester, UK; and the Westmead Hospital Clinical School and The George Institute for Global Health (R.I.L.), University of Sydney, Australia
| | - Gillian Potter
- From the Division of Neuroimaging Sciences (G.M., Z.M., A.J.F., G.C., J.M.W.) and the Division of Clinical Neurosciences (P.A.G.S.), University of Edinburgh, UK; the Department of Neuroradiology (R.v.K.), Dresden University Stroke Centre, Germany; Danderyd Hospital (A.v.H.), Stockholm, Sweden; Neuroradiology (N.B.), James Cook University Hospital, Middlesborough, UK; School of Pathology and Laboratory Medicine (L.C.), University of Western Australia, Perth; Cliniques Universitaires St Luc (A.P.), Neurologie, Belgium; Stroke Center (A.A.), Sacro Cuore-Don Calabria Hospital, Negrar, Italy; the Department of Neuroradiology (G.P.), Salford Royal NHS Foundation Trust, Manchester, UK; and the Westmead Hospital Clinical School and The George Institute for Global Health (R.I.L.), University of Sydney, Australia
| | - Geoff Cohen
- From the Division of Neuroimaging Sciences (G.M., Z.M., A.J.F., G.C., J.M.W.) and the Division of Clinical Neurosciences (P.A.G.S.), University of Edinburgh, UK; the Department of Neuroradiology (R.v.K.), Dresden University Stroke Centre, Germany; Danderyd Hospital (A.v.H.), Stockholm, Sweden; Neuroradiology (N.B.), James Cook University Hospital, Middlesborough, UK; School of Pathology and Laboratory Medicine (L.C.), University of Western Australia, Perth; Cliniques Universitaires St Luc (A.P.), Neurologie, Belgium; Stroke Center (A.A.), Sacro Cuore-Don Calabria Hospital, Negrar, Italy; the Department of Neuroradiology (G.P.), Salford Royal NHS Foundation Trust, Manchester, UK; and the Westmead Hospital Clinical School and The George Institute for Global Health (R.I.L.), University of Sydney, Australia
| | - Peter A G Sandercock
- From the Division of Neuroimaging Sciences (G.M., Z.M., A.J.F., G.C., J.M.W.) and the Division of Clinical Neurosciences (P.A.G.S.), University of Edinburgh, UK; the Department of Neuroradiology (R.v.K.), Dresden University Stroke Centre, Germany; Danderyd Hospital (A.v.H.), Stockholm, Sweden; Neuroradiology (N.B.), James Cook University Hospital, Middlesborough, UK; School of Pathology and Laboratory Medicine (L.C.), University of Western Australia, Perth; Cliniques Universitaires St Luc (A.P.), Neurologie, Belgium; Stroke Center (A.A.), Sacro Cuore-Don Calabria Hospital, Negrar, Italy; the Department of Neuroradiology (G.P.), Salford Royal NHS Foundation Trust, Manchester, UK; and the Westmead Hospital Clinical School and The George Institute for Global Health (R.I.L.), University of Sydney, Australia
| | - Richard I Lindley
- From the Division of Neuroimaging Sciences (G.M., Z.M., A.J.F., G.C., J.M.W.) and the Division of Clinical Neurosciences (P.A.G.S.), University of Edinburgh, UK; the Department of Neuroradiology (R.v.K.), Dresden University Stroke Centre, Germany; Danderyd Hospital (A.v.H.), Stockholm, Sweden; Neuroradiology (N.B.), James Cook University Hospital, Middlesborough, UK; School of Pathology and Laboratory Medicine (L.C.), University of Western Australia, Perth; Cliniques Universitaires St Luc (A.P.), Neurologie, Belgium; Stroke Center (A.A.), Sacro Cuore-Don Calabria Hospital, Negrar, Italy; the Department of Neuroradiology (G.P.), Salford Royal NHS Foundation Trust, Manchester, UK; and the Westmead Hospital Clinical School and The George Institute for Global Health (R.I.L.), University of Sydney, Australia
| | - Joanna M Wardlaw
- From the Division of Neuroimaging Sciences (G.M., Z.M., A.J.F., G.C., J.M.W.) and the Division of Clinical Neurosciences (P.A.G.S.), University of Edinburgh, UK; the Department of Neuroradiology (R.v.K.), Dresden University Stroke Centre, Germany; Danderyd Hospital (A.v.H.), Stockholm, Sweden; Neuroradiology (N.B.), James Cook University Hospital, Middlesborough, UK; School of Pathology and Laboratory Medicine (L.C.), University of Western Australia, Perth; Cliniques Universitaires St Luc (A.P.), Neurologie, Belgium; Stroke Center (A.A.), Sacro Cuore-Don Calabria Hospital, Negrar, Italy; the Department of Neuroradiology (G.P.), Salford Royal NHS Foundation Trust, Manchester, UK; and the Westmead Hospital Clinical School and The George Institute for Global Health (R.I.L.), University of Sydney, Australia.
| | | |
Collapse
|
27
|
Medlin F, Amiguet M, Vanacker P, Michel P. Influence of Arterial Occlusion on Outcome After Intravenous Thrombolysis for Acute Ischemic Stroke. Stroke 2015; 46:126-31. [DOI: 10.1161/strokeaha.114.006408] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Friedrich Medlin
- From the Service of Neurology, Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (F.M., P.M.); Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland (M.A.); Department of Neurology, University Hospital Antwerp, Belgium (P.V.); and University of Lausanne, Lausanne, Switzerland (P.M.)
| | - Michael Amiguet
- From the Service of Neurology, Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (F.M., P.M.); Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland (M.A.); Department of Neurology, University Hospital Antwerp, Belgium (P.V.); and University of Lausanne, Lausanne, Switzerland (P.M.)
| | - Peter Vanacker
- From the Service of Neurology, Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (F.M., P.M.); Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland (M.A.); Department of Neurology, University Hospital Antwerp, Belgium (P.V.); and University of Lausanne, Lausanne, Switzerland (P.M.)
| | - Patrik Michel
- From the Service of Neurology, Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (F.M., P.M.); Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland (M.A.); Department of Neurology, University Hospital Antwerp, Belgium (P.V.); and University of Lausanne, Lausanne, Switzerland (P.M.)
| |
Collapse
|
28
|
Abstract
Intravenous thrombolysis (IVT) with alteplase remains the standard treatment for acute ischemic stroke. Although IVT can be started up to 4.5 hours after symptoms' onset, it is all the more effective and safe when started early. It allows a 10% absolute reduction in the risk of handicap or death at 3 months, despite a 2-7% risk of symptomatic intracranial hemorrhage. Current research efforts involve firstly trying to treat a larger proportion of patients by overcoming some of the contraindications to IVT and secondly assessing combined or alternative treatments to achieve a higher early recanalization rate.
Collapse
Affiliation(s)
- G Turc
- Stroke unit, Sainte-Anne hospital, 1, rue Cabanis, 75014 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, France; Inserm UMR S894, France.
| | - C Isabel
- Stroke unit, Sainte-Anne hospital, 1, rue Cabanis, 75014 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, France
| | - D Calvet
- Stroke unit, Sainte-Anne hospital, 1, rue Cabanis, 75014 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, France; Inserm UMR S894, France
| |
Collapse
|